SlideShare uma empresa Scribd logo
1 de 65
Baixar para ler offline
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Updates in Colorectal Cancer
2016
Kristen K. Ciombor, MD, MSCI
Assistant Professor
Division of Medical Oncology
Outline
§ Primary tumor sidedness in colorectal cancer
§  CALGB/SWOG 80405
§ Immunotherapy in colorectal and anal cancer
§  Immunoscore in early stage colon cancer
§  Pembrolizumab in MSI-H mCRC
§  Nivolumab +/- ipilimumab in mCRC
§  Cobimetinib + atezolizumab in MSS mCRC
§  Nivolumab in metastatic anal cancer
2
Primary Tumor
Sidedness in
Colorectal
Cancer (CRC)
3
Impact of primary tumor location on
Overall Survival and Progression Free Survival
in patients with metastatic colorectal cancer:
Analysis of CALGB/SWOG 80405 (Alliance)
A Venook, D Niedzwiecki, F Innocenti, B Fruth, C Greene, BH O’Neil,
J Shaw, J Atkins, LE Horvath, B Polite, JA Meyerhardt, EM O’Reilly,
R Goldberg, HS Hochster, CD Blanke, R Schilsky, RJ Mayer, M Bertagnolli,
HJ Lenz for SWOG and the ALLIANCE
CALGB/SWOG 80405
Chemo + Cetuximab
Chemo + Bevacizumab
1ST LINE
MET / ADVANCED
COLORECTAL
KRAS wt
FOLFIRI
or
FOLFOX
MD choice
ASCO, JUNE, 2014 Chemo + Cetuximab
OS = 32.0 mos
PFS = 11.4 mos
Chemo + Bevacizumab
OS = 31.2 mos
PFS = 11.3 mosN = 1137
CONCLUSION: NO DIFFERENCE
OS better than anticipated in both arms:
Treatment effect and/or Patient selection
All RAS wt
ESMO, SEP, 2014
N = 526
CALGB 80405: Side of primary tumor
Methods
•  Population
–  KRAS wt pts in main analysis
–  Pre-amendment KRAS mut pts
•  Data extraction
–  Study chart, other supporting information if available
•  Side of 1° determination
–  Definitive information:
•  Colonoscopy, surgical or imaging report
Presented by:
Presented by:
80405: Side of Primary Tumors
LEFT
N = 732
(68%)
RIGHT
N = 293
(27%)
TRANSVERSE N = 66
COULD NOT
DETERMINE
N = 46
Bettington, et al. Histopathology. 2013.
Embryology: The origin of the colon
RIGHT COLON
LEFT COLON
80405: Overall Survival by Sidedness
Presented by:
Side N (Events)
Median
(95% CI)
HR
(95% CI)
p
Left 732 (550)
33.3
(31.4-35.7) 1.55
(1.32-1.82) 
< 0.0001
Right 293 (242)
19.4
(16.7-23.6)
Right
Left
80405: OS by Sidedness (Bevacizumab)
Presented by:
Side N (Events)
Median
(95% CI)
HR(95% CI) p
Left 356 (280)
31.4
(28.3-33.6)
1.32
(1.05-1.65)
 
0.01
 
Right 150 (121)
24.2
(17.9-30.3)
LeftRight
80405: OS by Sidedness (Cetuximab)
Presented by:
Side N (Events)
Median
(95% CI)
HR
(95% CI)
p
Left 376 (270)
36.0
(32.6-40.3)
1.87
(1.48-2.32)
 
<0.0001
 
Right 143 (121)
16.7
(13.1-19.4)
Left
Right
80405: Sidedness is Prognostic
Overall Survival (OS)
Presented by:
KRAS wt
N = 1025
Right 1°
Median OS
(mos)
Left 1°
Median OS
(mos)
Hazard Ratio
95% CI
(adjusted*)
P (adjusted*)
All pts 19.4 33.3 1.55 (1.32,1.82) P < 0.0001
Cet 16.7 36.0 1.87 (1.48, 2.32) P < 0.0001
Bev 24.2 31.4 1.32 (1.05, 1.65) P = 0.01
*Adjusted for biologic, protocol chemotherapy, prior adjuvant therapy, prior RT, age, sex,
synchronous disease, in place primary, liver metastases
19.3 MONTHS IS A BIG DIFFERENCE !!
80405: Overall Survival by Sidedness and Biologic
Presented by:
31.4 (28.3-33.6)
36.0 (32.6-40.3)
24.2 (17.9-30.3)
16.7 (13.1-19.4)
Summary of Primary Tumor Sidedness in mCRC
§ Patients with R-sided primaries had much worse
outcomes than pts with L-sided primaries,
independent of biologic arm (prognostic)
§ 1st line cetuximab and bevacizumab have different
treatment effects in sidedness subgroups
§ Sidedness is likely a surrogate for tumor biology
§ Future trials to stratify patients by primary sidedness
§ Remember: this is a retrospective ad hoc analysis;
these results will factor in when making tx decisions
but this is not the whole story
14
Immunoscore in
Early Stage
Colon Cancer
15
Slide 1
Presented By Jerome Galon at 2016 ASCO Annual Meeting
Slide 6
Presented By Jerome Galon at 2016 ASCO Annual Meeting
Slide 11
Presented By Jerome Galon at 2016 ASCO Annual Meeting
Slide 14
Presented By Jerome Galon at 2016 ASCO Annual Meeting
Slide 18
Presented By Jerome Galon at 2016 ASCO Annual Meeting
Slide 22
Presented By Jerome Galon at 2016 ASCO Annual Meeting
Summary of Immunoscore in Early Stage Colon CA
§ Time to recurrence was significantly longer in patients
with stage I/II/III colon cancer and high immunoscore
§ Immunoscore is significant in multivariate analyses in all
cohorts (TS, IVS, EVS)
§ Potential identification of a high-risk stage II group
§ Immunoscore predicts TTR, DFS and OS
§ How much is microsatellite instability contributing?
§ Future immune-based assay for cancer: TNM-Immune?
22
Pembrolizumab
in MSI-H mCRC
23
Slide 1
Presented By Dung Le at 2016 ASCO Annual Meeting
Slide 2
Presented By Dung Le at 2016 ASCO Annual Meeting
Slide 5
Presented By Dung Le at 2016 ASCO Annual Meeting
Slide 8
Presented By Dung Le at 2016 ASCO Annual Meeting
Slide 11
Presented By Dung Le at 2016 ASCO Annual Meeting
Slide 15
Presented By Dung Le at 2016 ASCO Annual Meeting
Slide 18
Presented By Dung Le at 2016 ASCO Annual Meeting
Slide 19
Presented By Dung Le at 2016 ASCO Annual Meeting
Summary of Pembrolizumab in MSI-H mCRC
§ PD-1 blockade with pembrolizumab is highly active
in dMMR mCRC
§ Complete and durable responses are seen in >50%
of patients
§ 18% have reached the two year mark on tx and
patients are under surveillance
§ Next/current trials: single agent pembrolizumab in 1st
line MSI-H mCRC, adjuvant trial, pembro + FOLFOX
32
Nivolumab +/-
Ipilimumab in
mCRC
33
Nivolumab ± Ipilimumab in Treatment of Patients With Metastatic Colorectal Cancer With and Without High Microsatellite Instability: <br />CheckMate 142 Interim Results
Presented By Michael Overman at 2016 ASCO Annual Meeting
Ipilimumab and Nivolumab <br />Mechanisms of Action
Presented By Michael Overman at 2016 ASCO Annual Meeting
Phase 2 CheckMate 142 Study Design: Microsatellite Stable (MSS) Cohort
Presented By Michael Overman at 2016 ASCO Annual Meeting
Phase 2 CheckMate 142 Study Design: <br />MSI-H Cohort
Presented By Michael Overman at 2016 ASCO Annual Meeting
Investigator-Assessed Best Overall Response in <br />Patients With MSI-H Receiving Nivolumab Monotherapy
Presented By Michael Overman at 2016 ASCO Annual Meeting
Investigator-Assessed Best Overall Response in <br />Patients With MSI-H Receiving Nivolumab + Ipilimumab
Presented By Michael Overman at 2016 ASCO Annual Meeting
Best Reduction in Target Lesion Size <br />in Patients With MSI-H
Presented By Michael Overman at 2016 ASCO Annual Meeting
OS in Patients With MSI-H<br />Nivolumab ± Ipilimumab in Metastatic CRC
Presented By Michael Overman at 2016 ASCO Annual Meeting
Treatment-Related Adverse Events <br />in ≥ 15% of Patients With MSI-H
Presented By Michael Overman at 2016 ASCO Annual Meeting
<br />Summary of Efficacy in Patients With MSS<br />Nivolumab ± Ipilimumab in Metastatic CRC
Presented By Michael Overman at 2016 ASCO Annual Meeting
Summary of Nivo +/- Ipi in mCRC
§ Nivolumab monotherapy and nivo + ipi showed
encouraging activity in MSI-H mCRC (interim analysis)
§ Responses were durable in MSI-H patients
§ Tolerable safety profiles but increasing toxicities with
combination therapy, consistent w/ observations in
other solid tumors
§ Need final analysis prior to next trials
44
Cobimetinib +
Atezolizumab in
MSS mCRC
45
Clinical activity and safety of cobimetinib and atezolizumab in colorectal cancer
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Slide 3
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Atezolizumab: An Anti-PDL1 Antibody
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
PD-L1 and MEK Inhibition: A Rational Combination
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Phase Ib Dose Escalation and Cohort Expansion Study (NCT01988896)
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Safety Summary
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Safety: Treatment-related AEs
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Efficacy: Confirmed Objective Response
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Efficacy: Change in Tumor Burden
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Efficacy: Duration of Treatment and Response
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Summary of Cobi + Atezo in MSS mCRC
§ Cobimetinib + atezolizumab was fairly tolerated in
pts with refractory MSS mCRC
§ Combination therapy resulted in higher clinical
response rate (17%) and 6-month OS (72%) than
expected with either agent alone
§ Cobi may sensitize tumors to atezo by increasing
MHC I expression on tumor cells, promoting
intratumoral CD8 T cell accumulation
§ Next/current trial: Phase Ib expansion and phase III
trial both ongoing
56
Nivolumab in
Metastatic Anal
Cancer
57
NCI9673: A Multi-Institutional ETCTN
Phase II Study of Nivolumab in Refractory
Metastatic Squamous Cell Carcinoma of
the Anal Canal (SCCA)
V. Morris1, K. Ciombor2, M.E. Salem3, H. Nimeiri4, S. Iqbal5, P. Singh6, B. Polite7,
D. Deming8, E. Chan9, J.L. Wade10, T.S. Bekaii-Saab2, H.E. Uronis11, M.G. Pasia1, G. Bland1,
R.A. Wolff1, A. Ohinata1, C. Ohaji1, J.E. Rogers1, P. Sharma1, C. Eng1
1The University of Texas MD Anderson Cancer Center, Houston, TX; 2The Ohio State University Comprehensive Cancer Center,
Arthur G. James Cancer Hospital, Columbus, OH; 3Lombardi Comprehensive Cancer Center, Georgetown University, Washington,
DC; 4Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; 5University of Southern California/
Norris Comprehensive Cancer Center, Los Angeles, CA; 6Washington University, Siteman Cancer Center, St. Louis, MO; 7The
University of Chicago, Chicago, IL; 8University of Wisconsin Hospitals and Clinics, Madison, WI; 9Vanderbilt University Medical
Center, Nashville, TN; 10Cancer Care Center of Decatur, Decatur, IL; 11Duke University Medical Center, Durham, NC
•  Approximately 80-95% of cases
are linked to infection with human
papillomavirus (HPV).
•  The role of HPV in the
tumorigenesis of SCCA provides
rationale for the use of immune
checkpoint blockade agents as a
novel therapy for treatment of
patients with a virally driven
disease.
Presented by: Cathy Eng, MD
Rationale for Nivolumab in Metastatic SCCA:
Morris VK et al. The Oncologist, 2015, Sarup-Hansen E et al. J Clin Oncol ,2014
NCI#9673: Phase II Design of Nivolumab in Metastatic SCCA
Presented by: Cathy Eng, MD
Patients with metastatic squamous cell carcinoma of the anal canal
- Treated with at least one prior therapy for metastatic disease
- No prior immune therapies received as part of cancer treatment
12 patients treated initially with nivolumab
3mg/kg IV every 2 weeks
Patients will be followed for best response
using RECIST criteria 1.1
0 responses ≥1 response
Stop trial
Expand trial to include 25
additional patients with
metastatic SCCA
* HIV+ patients allowed
•  Rapid enrollment in < 6 months
•  Closed to enrollment as of 11/01/15
•  Simon Optimal, two-
stage phase II study,
Ho: p ≤ 0.05 and an
alternative hypothesis
Ha: p ≥ 0.20,
•  α = 0.10 and a β = 0.10
Primary Endpoint: Response Rate
Presented by: Cathy Eng, MD
Response Rate N (%)
CR 2 (5.4%)
PR 7 (18.9%)
SD 17 (45.9%)
PD 8 (21.6%)
Unevaluable 3 (8.1%)
ORR (ITT, N=37) 9 (24.3%)
ORR (Evaluable,
N=34) 9 (26.5%)
Data cutoff date: 5/15/16
-1 0 0
-9 0
-8 0
-7 0
-6 0
-5 0
-4 0
-3 0
-2 0
-1 0
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
P a tie n t
%targetlesionreduction
frombaselinebyRECIST1.1
P ro g re s s iv e D is e a s e
S ta b le D is e a s e
P a rtia l R e s p o n s e
P R
P D
NCI#9673: Response Rate
N=37 (ITT)
N=34 (evaluable
for RR)
2 CR’s
7 PR’s
Presented by: Cathy Eng, MD
Patients
CR
NCI#9673 Toxicities of Therapy
Toxicity (N=37) Grade (%)
1 2 3 4
Fatigue 17 (46) 7 (19) 1 (3) -
Anemia 13 (35) 11 (30) 2 (5) -
Rash 8 (22) 2 (5) 1 (3) -
Constipation 8 (22) 2 (5) - -
Diarrhea 8 (22) - - -
Anorexia 5 (14) 4 (11) - -
Weight loss 5 (14) 1 (3) - -
Arthralgia 3 (8) 3 (8) - -
Hyperglycemia 3 (8) 1 (3) - -
Lymphedema 1 (3) 1 (3) - -
Pneumonitis - 1 (3) - -
Nausea 2 (5) - - -
Hypothyroidism 1 (3) 1 (3) 1 (3) -
Presented by: Cathy Eng, MD
Summary of Nivolumab in Anal Cancer
§ First prospective phase II trial completed in refractory
mSCC of anal canal; <6 month accrual
§ Encouraging response rates in a “rare” cancer with
few treatment options for metastatic disease
§ Nivolumab was well tolerated, even in HIV+ patients
§ Future trial: amendment of NCI 9673—pilot of
nivolumab + ipilimumab
64
Thank You
To learn more about Ohio State’s cancer
program, please visit cancer.osu.edu or
follow us in social media:
65

Mais conteúdo relacionado

Mais procurados

SBRT IN LIVER TUMOURS- DR UPASNA.pptx
SBRT IN LIVER TUMOURS- DR UPASNA.pptxSBRT IN LIVER TUMOURS- DR UPASNA.pptx
SBRT IN LIVER TUMOURS- DR UPASNA.pptxUpasna Saxena
 
Management of metastatic colorectal cancer
Management of metastatic colorectal cancerManagement of metastatic colorectal cancer
Management of metastatic colorectal cancerMohamed Abdulla
 
ESMO Oesophageal cancer webinar.pdf
ESMO Oesophageal cancer webinar.pdfESMO Oesophageal cancer webinar.pdf
ESMO Oesophageal cancer webinar.pdfFarah Fara
 
Management of ewings sarcoma
Management of ewings sarcomaManagement of ewings sarcoma
Management of ewings sarcomaSameer Rastogi
 
ADJUANT TREATMENT IN CA ENDOMETRIUM
ADJUANT TREATMENT IN CA ENDOMETRIUMADJUANT TREATMENT IN CA ENDOMETRIUM
ADJUANT TREATMENT IN CA ENDOMETRIUMPaul George
 
LUNG CANCER MANAGEMENT IN LOW RESOURCE SETTINGS
LUNG CANCER MANAGEMENT IN LOW RESOURCE SETTINGSLUNG CANCER MANAGEMENT IN LOW RESOURCE SETTINGS
LUNG CANCER MANAGEMENT IN LOW RESOURCE SETTINGSKanhu Charan
 
Radiotherapy For Non Small Cell Lung Cancer
Radiotherapy For Non Small Cell Lung CancerRadiotherapy For Non Small Cell Lung Cancer
Radiotherapy For Non Small Cell Lung Cancerfondas vakalis
 
Rectal cancer Preoperative Radiotherapy- Short vs long course
Rectal cancer Preoperative Radiotherapy- Short vs long courseRectal cancer Preoperative Radiotherapy- Short vs long course
Rectal cancer Preoperative Radiotherapy- Short vs long courseGaurav Kumar
 
Approach towards reirradiation
Approach towards reirradiationApproach towards reirradiation
Approach towards reirradiationKanhu Charan
 
Non small cell lung cancer copy
Non small cell lung cancer   copyNon small cell lung cancer   copy
Non small cell lung cancer copyankitapandey63
 
Immunotherapy for Colorectal Cancer
Immunotherapy for Colorectal CancerImmunotherapy for Colorectal Cancer
Immunotherapy for Colorectal Cancerspa718
 
metastatic colorectal cancer; a new chapter in the story
metastatic colorectal cancer; a new chapter in the storymetastatic colorectal cancer; a new chapter in the story
metastatic colorectal cancer; a new chapter in the storyMohamed Abdulla
 
LANDMARK TRIALS IN BREAST CANCER
LANDMARK TRIALS IN BREAST CANCERLANDMARK TRIALS IN BREAST CANCER
LANDMARK TRIALS IN BREAST CANCERAaditya Prakash
 
Cervix External Beam Radiotherapy techniques
Cervix External Beam Radiotherapy techniquesCervix External Beam Radiotherapy techniques
Cervix External Beam Radiotherapy techniquesAnimesh Agrawal
 
parsport trial ppt
parsport trial pptparsport trial ppt
parsport trial pptGaurav Kumar
 
Ablation of HCC
Ablation of HCCAblation of HCC
Ablation of HCCPAIRS WEB
 
Gastric cancer discussion slides final version.pptnew.ppt
Gastric cancer discussion slides final version.pptnew.pptGastric cancer discussion slides final version.pptnew.ppt
Gastric cancer discussion slides final version.pptnew.pptzoezettemarc
 

Mais procurados (20)

APBI-Dr Kiran
APBI-Dr Kiran APBI-Dr Kiran
APBI-Dr Kiran
 
SBRT IN LIVER TUMOURS- DR UPASNA.pptx
SBRT IN LIVER TUMOURS- DR UPASNA.pptxSBRT IN LIVER TUMOURS- DR UPASNA.pptx
SBRT IN LIVER TUMOURS- DR UPASNA.pptx
 
Trials in esophageal cancer.pptx
Trials in esophageal cancer.pptxTrials in esophageal cancer.pptx
Trials in esophageal cancer.pptx
 
Management of metastatic colorectal cancer
Management of metastatic colorectal cancerManagement of metastatic colorectal cancer
Management of metastatic colorectal cancer
 
ESMO Oesophageal cancer webinar.pdf
ESMO Oesophageal cancer webinar.pdfESMO Oesophageal cancer webinar.pdf
ESMO Oesophageal cancer webinar.pdf
 
Management of ewings sarcoma
Management of ewings sarcomaManagement of ewings sarcoma
Management of ewings sarcoma
 
ADJUANT TREATMENT IN CA ENDOMETRIUM
ADJUANT TREATMENT IN CA ENDOMETRIUMADJUANT TREATMENT IN CA ENDOMETRIUM
ADJUANT TREATMENT IN CA ENDOMETRIUM
 
LUNG CANCER MANAGEMENT IN LOW RESOURCE SETTINGS
LUNG CANCER MANAGEMENT IN LOW RESOURCE SETTINGSLUNG CANCER MANAGEMENT IN LOW RESOURCE SETTINGS
LUNG CANCER MANAGEMENT IN LOW RESOURCE SETTINGS
 
Radiotherapy For Non Small Cell Lung Cancer
Radiotherapy For Non Small Cell Lung CancerRadiotherapy For Non Small Cell Lung Cancer
Radiotherapy For Non Small Cell Lung Cancer
 
Rectal cancer Preoperative Radiotherapy- Short vs long course
Rectal cancer Preoperative Radiotherapy- Short vs long courseRectal cancer Preoperative Radiotherapy- Short vs long course
Rectal cancer Preoperative Radiotherapy- Short vs long course
 
Approach towards reirradiation
Approach towards reirradiationApproach towards reirradiation
Approach towards reirradiation
 
Non small cell lung cancer copy
Non small cell lung cancer   copyNon small cell lung cancer   copy
Non small cell lung cancer copy
 
Immunotherapy for Colorectal Cancer
Immunotherapy for Colorectal CancerImmunotherapy for Colorectal Cancer
Immunotherapy for Colorectal Cancer
 
metastatic colorectal cancer; a new chapter in the story
metastatic colorectal cancer; a new chapter in the storymetastatic colorectal cancer; a new chapter in the story
metastatic colorectal cancer; a new chapter in the story
 
Rectal cancer chemo and radiotherapy trials
Rectal cancer chemo and radiotherapy trialsRectal cancer chemo and radiotherapy trials
Rectal cancer chemo and radiotherapy trials
 
LANDMARK TRIALS IN BREAST CANCER
LANDMARK TRIALS IN BREAST CANCERLANDMARK TRIALS IN BREAST CANCER
LANDMARK TRIALS IN BREAST CANCER
 
Cervix External Beam Radiotherapy techniques
Cervix External Beam Radiotherapy techniquesCervix External Beam Radiotherapy techniques
Cervix External Beam Radiotherapy techniques
 
parsport trial ppt
parsport trial pptparsport trial ppt
parsport trial ppt
 
Ablation of HCC
Ablation of HCCAblation of HCC
Ablation of HCC
 
Gastric cancer discussion slides final version.pptnew.ppt
Gastric cancer discussion slides final version.pptnew.pptGastric cancer discussion slides final version.pptnew.ppt
Gastric cancer discussion slides final version.pptnew.ppt
 

Semelhante a ASCO Review 2016 Colorectal Cancer

Secuencia en cáncer de colon metastásico
Secuencia en cáncer de colon metastásicoSecuencia en cáncer de colon metastásico
Secuencia en cáncer de colon metastásicoMauricio Lema
 
Neoadjuvant therapy of rectal cancer
Neoadjuvant therapy of rectal cancerNeoadjuvant therapy of rectal cancer
Neoadjuvant therapy of rectal cancerMohamed Abdulla
 
GI ASCO 2019 Updates – January 2019 Webinar
GI ASCO 2019 Updates – January 2019 WebinarGI ASCO 2019 Updates – January 2019 Webinar
GI ASCO 2019 Updates – January 2019 WebinarFight Colorectal Cancer
 
Astellas meeting, crpc- what we have in 2019
Astellas   meeting, crpc- what we have in 2019Astellas   meeting, crpc- what we have in 2019
Astellas meeting, crpc- what we have in 2019Mohamed Abdulla
 
Triple Negative Breast Cancer
Triple Negative Breast CancerTriple Negative Breast Cancer
Triple Negative Breast CancerMohamed Abdulla
 
Colon Cancer Updates - 2015/2016 - Based on ASCO GI 2016
Colon Cancer Updates - 2015/2016 - Based on ASCO GI 2016Colon Cancer Updates - 2015/2016 - Based on ASCO GI 2016
Colon Cancer Updates - 2015/2016 - Based on ASCO GI 2016Mohamed Abdulla
 
Immunotherapy Efforts and Fight CRC Dec 13 2017 Webinar
Immunotherapy Efforts and Fight CRC Dec 13 2017 WebinarImmunotherapy Efforts and Fight CRC Dec 13 2017 Webinar
Immunotherapy Efforts and Fight CRC Dec 13 2017 WebinarFight Colorectal Cancer
 
Renal cell carcinoma ( RCC )ADJUVANT TRIALS.pptx
Renal cell carcinoma ( RCC )ADJUVANT TRIALS.pptxRenal cell carcinoma ( RCC )ADJUVANT TRIALS.pptx
Renal cell carcinoma ( RCC )ADJUVANT TRIALS.pptxAnandHosalli
 
MANAGEMENTOF METASTATIC OR ADVANCED GASTRIC CANCER : FIRST LINE OPTIONS
MANAGEMENTOF METASTATIC OR ADVANCED GASTRIC CANCER : FIRST LINE OPTIONSMANAGEMENTOF METASTATIC OR ADVANCED GASTRIC CANCER : FIRST LINE OPTIONS
MANAGEMENTOF METASTATIC OR ADVANCED GASTRIC CANCER : FIRST LINE OPTIONSMohamed Abdulla
 
Chemoradiotherapy Anal canal cancer.pptx
Chemoradiotherapy Anal canal cancer.pptxChemoradiotherapy Anal canal cancer.pptx
Chemoradiotherapy Anal canal cancer.pptxAtulGupta369
 
Breast cancer oncotype-dx.. by dr.Kamel Farag, MD
Breast cancer oncotype-dx.. by dr.Kamel Farag, MDBreast cancer oncotype-dx.. by dr.Kamel Farag, MD
Breast cancer oncotype-dx.. by dr.Kamel Farag, MDKamelFarag4
 
Renal Cell Carcinoma Diagnosis And Management
Renal Cell Carcinoma Diagnosis And ManagementRenal Cell Carcinoma Diagnosis And Management
Renal Cell Carcinoma Diagnosis And ManagementRHMBONCO
 
How I treat Relapsed Ca Ovary
How I treat Relapsed Ca OvaryHow I treat Relapsed Ca Ovary
How I treat Relapsed Ca OvaryChandan K Das
 
2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar
2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar
2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinarFight Colorectal Cancer
 
Right vs Left Sidedness in Colon Cancer.pptx
Right vs Left Sidedness in Colon Cancer.pptxRight vs Left Sidedness in Colon Cancer.pptx
Right vs Left Sidedness in Colon Cancer.pptxDrMalcolmBrigden1
 
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásicoActualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásicoMauricio Lema
 
Management of Gastric Cancer in 2017
Management of Gastric Cancer in 2017Management of Gastric Cancer in 2017
Management of Gastric Cancer in 2017Mohamed Abdulla
 
Chemotherapy in rhabdomyosarcoma
Chemotherapy in rhabdomyosarcomaChemotherapy in rhabdomyosarcoma
Chemotherapy in rhabdomyosarcomaSameer Rastogi
 
Biomarkers in Ovarian Cancer
Biomarkers in Ovarian CancerBiomarkers in Ovarian Cancer
Biomarkers in Ovarian CancerMauricio Lema
 

Semelhante a ASCO Review 2016 Colorectal Cancer (20)

Secuencia en cáncer de colon metastásico
Secuencia en cáncer de colon metastásicoSecuencia en cáncer de colon metastásico
Secuencia en cáncer de colon metastásico
 
Neoadjuvant therapy of rectal cancer
Neoadjuvant therapy of rectal cancerNeoadjuvant therapy of rectal cancer
Neoadjuvant therapy of rectal cancer
 
GI ASCO 2019 Updates – January 2019 Webinar
GI ASCO 2019 Updates – January 2019 WebinarGI ASCO 2019 Updates – January 2019 Webinar
GI ASCO 2019 Updates – January 2019 Webinar
 
Astellas meeting, crpc- what we have in 2019
Astellas   meeting, crpc- what we have in 2019Astellas   meeting, crpc- what we have in 2019
Astellas meeting, crpc- what we have in 2019
 
Triple Negative Breast Cancer
Triple Negative Breast CancerTriple Negative Breast Cancer
Triple Negative Breast Cancer
 
Colon Cancer Updates - 2015/2016 - Based on ASCO GI 2016
Colon Cancer Updates - 2015/2016 - Based on ASCO GI 2016Colon Cancer Updates - 2015/2016 - Based on ASCO GI 2016
Colon Cancer Updates - 2015/2016 - Based on ASCO GI 2016
 
Immunotherapy Efforts and Fight CRC Dec 13 2017 Webinar
Immunotherapy Efforts and Fight CRC Dec 13 2017 WebinarImmunotherapy Efforts and Fight CRC Dec 13 2017 Webinar
Immunotherapy Efforts and Fight CRC Dec 13 2017 Webinar
 
Presentation ppt cancer
Presentation ppt cancerPresentation ppt cancer
Presentation ppt cancer
 
Renal cell carcinoma ( RCC )ADJUVANT TRIALS.pptx
Renal cell carcinoma ( RCC )ADJUVANT TRIALS.pptxRenal cell carcinoma ( RCC )ADJUVANT TRIALS.pptx
Renal cell carcinoma ( RCC )ADJUVANT TRIALS.pptx
 
MANAGEMENTOF METASTATIC OR ADVANCED GASTRIC CANCER : FIRST LINE OPTIONS
MANAGEMENTOF METASTATIC OR ADVANCED GASTRIC CANCER : FIRST LINE OPTIONSMANAGEMENTOF METASTATIC OR ADVANCED GASTRIC CANCER : FIRST LINE OPTIONS
MANAGEMENTOF METASTATIC OR ADVANCED GASTRIC CANCER : FIRST LINE OPTIONS
 
Chemoradiotherapy Anal canal cancer.pptx
Chemoradiotherapy Anal canal cancer.pptxChemoradiotherapy Anal canal cancer.pptx
Chemoradiotherapy Anal canal cancer.pptx
 
Breast cancer oncotype-dx.. by dr.Kamel Farag, MD
Breast cancer oncotype-dx.. by dr.Kamel Farag, MDBreast cancer oncotype-dx.. by dr.Kamel Farag, MD
Breast cancer oncotype-dx.. by dr.Kamel Farag, MD
 
Renal Cell Carcinoma Diagnosis And Management
Renal Cell Carcinoma Diagnosis And ManagementRenal Cell Carcinoma Diagnosis And Management
Renal Cell Carcinoma Diagnosis And Management
 
How I treat Relapsed Ca Ovary
How I treat Relapsed Ca OvaryHow I treat Relapsed Ca Ovary
How I treat Relapsed Ca Ovary
 
2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar
2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar
2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar
 
Right vs Left Sidedness in Colon Cancer.pptx
Right vs Left Sidedness in Colon Cancer.pptxRight vs Left Sidedness in Colon Cancer.pptx
Right vs Left Sidedness in Colon Cancer.pptx
 
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásicoActualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
 
Management of Gastric Cancer in 2017
Management of Gastric Cancer in 2017Management of Gastric Cancer in 2017
Management of Gastric Cancer in 2017
 
Chemotherapy in rhabdomyosarcoma
Chemotherapy in rhabdomyosarcomaChemotherapy in rhabdomyosarcoma
Chemotherapy in rhabdomyosarcoma
 
Biomarkers in Ovarian Cancer
Biomarkers in Ovarian CancerBiomarkers in Ovarian Cancer
Biomarkers in Ovarian Cancer
 

Mais de OSUCCC - James

In Vitro ADMET Considerations for Drug Discovery and Lead Generation
In Vitro ADMET Considerations for Drug Discovery and Lead GenerationIn Vitro ADMET Considerations for Drug Discovery and Lead Generation
In Vitro ADMET Considerations for Drug Discovery and Lead GenerationOSUCCC - James
 
Cell-Based Ion Channel and Cardiac Safety Assays
Cell-Based Ion Channel and Cardiac Safety AssaysCell-Based Ion Channel and Cardiac Safety Assays
Cell-Based Ion Channel and Cardiac Safety AssaysOSUCCC - James
 
In-Vivo Safety - Pre Ind Drug Development
In-Vivo Safety - Pre Ind Drug DevelopmentIn-Vivo Safety - Pre Ind Drug Development
In-Vivo Safety - Pre Ind Drug DevelopmentOSUCCC - James
 
The Path from Chemical Tool to Approvable Drug
The Path from Chemical Tool to Approvable DrugThe Path from Chemical Tool to Approvable Drug
The Path from Chemical Tool to Approvable DrugOSUCCC - James
 
Target Validation / Biochemical and Cellular Assay Development
Target Validation / Biochemical and Cellular Assay Development Target Validation / Biochemical and Cellular Assay Development
Target Validation / Biochemical and Cellular Assay Development OSUCCC - James
 
Intro to Ohio State's Drug Development Bootcamp: Practical Aspects of Positio...
Intro to Ohio State's Drug Development Bootcamp: Practical Aspects of Positio...Intro to Ohio State's Drug Development Bootcamp: Practical Aspects of Positio...
Intro to Ohio State's Drug Development Bootcamp: Practical Aspects of Positio...OSUCCC - James
 
Ohio State's ASH Review 2017 - Myeloproliferative Disorders
Ohio State's ASH Review 2017 - Myeloproliferative DisordersOhio State's ASH Review 2017 - Myeloproliferative Disorders
Ohio State's ASH Review 2017 - Myeloproliferative DisordersOSUCCC - James
 
Ohio State's ASH Review 2017 - Blood and Marrow Transplantation
Ohio State's ASH Review 2017 - Blood and Marrow TransplantationOhio State's ASH Review 2017 - Blood and Marrow Transplantation
Ohio State's ASH Review 2017 - Blood and Marrow TransplantationOSUCCC - James
 
Ohio State's ASH Review 2017 - Benign Hematology
Ohio State's ASH Review 2017 - Benign HematologyOhio State's ASH Review 2017 - Benign Hematology
Ohio State's ASH Review 2017 - Benign HematologyOSUCCC - James
 
Ohio State's ASH Review 2017 - Update in Myeloma
Ohio State's ASH Review 2017 - Update in MyelomaOhio State's ASH Review 2017 - Update in Myeloma
Ohio State's ASH Review 2017 - Update in MyelomaOSUCCC - James
 
Surgical (or Non-Surgical) Managment of Thyroid Cancer in the Era of "Over-Di...
Surgical (or Non-Surgical) Managment of Thyroid Cancer in the Era of "Over-Di...Surgical (or Non-Surgical) Managment of Thyroid Cancer in the Era of "Over-Di...
Surgical (or Non-Surgical) Managment of Thyroid Cancer in the Era of "Over-Di...OSUCCC - James
 
Genetic predisposition to papillary thyroid cancer by Albert de la Chapelle, ...
Genetic predisposition to papillary thyroid cancer by Albert de la Chapelle, ...Genetic predisposition to papillary thyroid cancer by Albert de la Chapelle, ...
Genetic predisposition to papillary thyroid cancer by Albert de la Chapelle, ...OSUCCC - James
 
Genetic Syndromes and Thyroid Cancer by Pamela Brock, MS, LGC
Genetic Syndromes and Thyroid Cancer by Pamela Brock, MS, LGCGenetic Syndromes and Thyroid Cancer by Pamela Brock, MS, LGC
Genetic Syndromes and Thyroid Cancer by Pamela Brock, MS, LGCOSUCCC - James
 
ASCO 2016 Review Neuro-oncology
ASCO 2016 Review Neuro-oncologyASCO 2016 Review Neuro-oncology
ASCO 2016 Review Neuro-oncologyOSUCCC - James
 
Melanoma ASCO Review Update 2016
Melanoma ASCO Review Update 2016Melanoma ASCO Review Update 2016
Melanoma ASCO Review Update 2016OSUCCC - James
 
ASCO Review 2016 Upper GI Cancers
ASCO Review 2016 Upper GI CancersASCO Review 2016 Upper GI Cancers
ASCO Review 2016 Upper GI CancersOSUCCC - James
 
ASCO 2016 Breast Cancer Review
ASCO 2016 Breast Cancer ReviewASCO 2016 Breast Cancer Review
ASCO 2016 Breast Cancer ReviewOSUCCC - James
 
ASCO 2016 Thoracic Review
ASCO 2016 Thoracic ReviewASCO 2016 Thoracic Review
ASCO 2016 Thoracic ReviewOSUCCC - James
 
ASCO Review 2016 Addressing Health Disparities
ASCO Review 2016 Addressing Health DisparitiesASCO Review 2016 Addressing Health Disparities
ASCO Review 2016 Addressing Health DisparitiesOSUCCC - James
 

Mais de OSUCCC - James (20)

In Vitro ADMET Considerations for Drug Discovery and Lead Generation
In Vitro ADMET Considerations for Drug Discovery and Lead GenerationIn Vitro ADMET Considerations for Drug Discovery and Lead Generation
In Vitro ADMET Considerations for Drug Discovery and Lead Generation
 
Cell-Based Ion Channel and Cardiac Safety Assays
Cell-Based Ion Channel and Cardiac Safety AssaysCell-Based Ion Channel and Cardiac Safety Assays
Cell-Based Ion Channel and Cardiac Safety Assays
 
In-Vivo Safety - Pre Ind Drug Development
In-Vivo Safety - Pre Ind Drug DevelopmentIn-Vivo Safety - Pre Ind Drug Development
In-Vivo Safety - Pre Ind Drug Development
 
The Path from Chemical Tool to Approvable Drug
The Path from Chemical Tool to Approvable DrugThe Path from Chemical Tool to Approvable Drug
The Path from Chemical Tool to Approvable Drug
 
Target Validation / Biochemical and Cellular Assay Development
Target Validation / Biochemical and Cellular Assay Development Target Validation / Biochemical and Cellular Assay Development
Target Validation / Biochemical and Cellular Assay Development
 
Intro to Ohio State's Drug Development Bootcamp: Practical Aspects of Positio...
Intro to Ohio State's Drug Development Bootcamp: Practical Aspects of Positio...Intro to Ohio State's Drug Development Bootcamp: Practical Aspects of Positio...
Intro to Ohio State's Drug Development Bootcamp: Practical Aspects of Positio...
 
Ohio State's ASH Review 2017 - Myeloproliferative Disorders
Ohio State's ASH Review 2017 - Myeloproliferative DisordersOhio State's ASH Review 2017 - Myeloproliferative Disorders
Ohio State's ASH Review 2017 - Myeloproliferative Disorders
 
Ohio State's ASH Review 2017 - Blood and Marrow Transplantation
Ohio State's ASH Review 2017 - Blood and Marrow TransplantationOhio State's ASH Review 2017 - Blood and Marrow Transplantation
Ohio State's ASH Review 2017 - Blood and Marrow Transplantation
 
Ohio State's ASH Review 2017 - Benign Hematology
Ohio State's ASH Review 2017 - Benign HematologyOhio State's ASH Review 2017 - Benign Hematology
Ohio State's ASH Review 2017 - Benign Hematology
 
Ohio State's ASH Review 2017 - Update in Myeloma
Ohio State's ASH Review 2017 - Update in MyelomaOhio State's ASH Review 2017 - Update in Myeloma
Ohio State's ASH Review 2017 - Update in Myeloma
 
Surgical (or Non-Surgical) Managment of Thyroid Cancer in the Era of "Over-Di...
Surgical (or Non-Surgical) Managment of Thyroid Cancer in the Era of "Over-Di...Surgical (or Non-Surgical) Managment of Thyroid Cancer in the Era of "Over-Di...
Surgical (or Non-Surgical) Managment of Thyroid Cancer in the Era of "Over-Di...
 
Genetic predisposition to papillary thyroid cancer by Albert de la Chapelle, ...
Genetic predisposition to papillary thyroid cancer by Albert de la Chapelle, ...Genetic predisposition to papillary thyroid cancer by Albert de la Chapelle, ...
Genetic predisposition to papillary thyroid cancer by Albert de la Chapelle, ...
 
Genetic Syndromes and Thyroid Cancer by Pamela Brock, MS, LGC
Genetic Syndromes and Thyroid Cancer by Pamela Brock, MS, LGCGenetic Syndromes and Thyroid Cancer by Pamela Brock, MS, LGC
Genetic Syndromes and Thyroid Cancer by Pamela Brock, MS, LGC
 
ASCO 2016 Review Neuro-oncology
ASCO 2016 Review Neuro-oncologyASCO 2016 Review Neuro-oncology
ASCO 2016 Review Neuro-oncology
 
Melanoma ASCO Review Update 2016
Melanoma ASCO Review Update 2016Melanoma ASCO Review Update 2016
Melanoma ASCO Review Update 2016
 
ASCO Review 2016 Upper GI Cancers
ASCO Review 2016 Upper GI CancersASCO Review 2016 Upper GI Cancers
ASCO Review 2016 Upper GI Cancers
 
ASCO 2016 Breast Cancer Review
ASCO 2016 Breast Cancer ReviewASCO 2016 Breast Cancer Review
ASCO 2016 Breast Cancer Review
 
ASCO 2016 Thoracic Review
ASCO 2016 Thoracic ReviewASCO 2016 Thoracic Review
ASCO 2016 Thoracic Review
 
ASCO Review 2016 Addressing Health Disparities
ASCO Review 2016 Addressing Health DisparitiesASCO Review 2016 Addressing Health Disparities
ASCO Review 2016 Addressing Health Disparities
 
Asco 2016 GU Review
Asco 2016 GU ReviewAsco 2016 GU Review
Asco 2016 GU Review
 

Último

Rishikesh Call Girls Service 6398383382 Real Russian Girls Looking Models
Rishikesh Call Girls Service 6398383382 Real Russian Girls Looking ModelsRishikesh Call Girls Service 6398383382 Real Russian Girls Looking Models
Rishikesh Call Girls Service 6398383382 Real Russian Girls Looking ModelsRupali Sharma
 
9316020077📞Majorda Beach Call Girls Numbers, Call Girls Whatsapp Numbers Ma...
9316020077📞Majorda Beach Call Girls  Numbers, Call Girls  Whatsapp Numbers Ma...9316020077📞Majorda Beach Call Girls  Numbers, Call Girls  Whatsapp Numbers Ma...
9316020077📞Majorda Beach Call Girls Numbers, Call Girls Whatsapp Numbers Ma...Goa cutee sexy top girl
 
Escorts Lahore || 🔞 03274100048 || Escort service in Lahore
Escorts Lahore || 🔞 03274100048 || Escort service in LahoreEscorts Lahore || 🔞 03274100048 || Escort service in Lahore
Escorts Lahore || 🔞 03274100048 || Escort service in LahoreDeny Daniel
 
Sexy Call Girl Dharmapuri Arshi 💚9058824046💚 Dharmapuri Escort Service
Sexy Call Girl Dharmapuri Arshi 💚9058824046💚 Dharmapuri Escort ServiceSexy Call Girl Dharmapuri Arshi 💚9058824046💚 Dharmapuri Escort Service
Sexy Call Girl Dharmapuri Arshi 💚9058824046💚 Dharmapuri Escort Servicejaanseema653
 
Sexy Call Girl Nagercoil Arshi 💚9058824046💚 Nagercoil Escort Service
Sexy Call Girl Nagercoil Arshi 💚9058824046💚 Nagercoil Escort ServiceSexy Call Girl Nagercoil Arshi 💚9058824046💚 Nagercoil Escort Service
Sexy Call Girl Nagercoil Arshi 💚9058824046💚 Nagercoil Escort Servicejaanseema653
 
AECS Layout Escorts (Bangalore) 9352852248 Women seeking Men Real Service
AECS Layout Escorts (Bangalore) 9352852248 Women seeking Men Real ServiceAECS Layout Escorts (Bangalore) 9352852248 Women seeking Men Real Service
AECS Layout Escorts (Bangalore) 9352852248 Women seeking Men Real ServiceAhmedabad Call Girls
 
Call Girls in Udaipur Girija Udaipur Call Girl ✔ VQRWTO ❤️ 100% offer with...
Call Girls in Udaipur  Girija  Udaipur Call Girl  ✔ VQRWTO ❤️ 100% offer with...Call Girls in Udaipur  Girija  Udaipur Call Girl  ✔ VQRWTO ❤️ 100% offer with...
Call Girls in Udaipur Girija Udaipur Call Girl ✔ VQRWTO ❤️ 100% offer with...mahaiklolahd
 
❤️Ludhiana Call Girls ☎️98157-77685☎️ Call Girl service in Ludhiana☎️Ludhiana...
❤️Ludhiana Call Girls ☎️98157-77685☎️ Call Girl service in Ludhiana☎️Ludhiana...❤️Ludhiana Call Girls ☎️98157-77685☎️ Call Girl service in Ludhiana☎️Ludhiana...
❤️Ludhiana Call Girls ☎️98157-77685☎️ Call Girl service in Ludhiana☎️Ludhiana...dilpreetentertainmen
 
(Deeksha) 💓 9920725232 💓High Profile Call Girls Navi Mumbai You Can Get The S...
(Deeksha) 💓 9920725232 💓High Profile Call Girls Navi Mumbai You Can Get The S...(Deeksha) 💓 9920725232 💓High Profile Call Girls Navi Mumbai You Can Get The S...
(Deeksha) 💓 9920725232 💓High Profile Call Girls Navi Mumbai You Can Get The S...Ahmedabad Call Girls
 
(Big Boobs Indian Girls) 💓 9257276172 💓High Profile Call Girls Jaipur You Can...
(Big Boobs Indian Girls) 💓 9257276172 💓High Profile Call Girls Jaipur You Can...(Big Boobs Indian Girls) 💓 9257276172 💓High Profile Call Girls Jaipur You Can...
(Big Boobs Indian Girls) 💓 9257276172 💓High Profile Call Girls Jaipur You Can...Joya Singh
 
👉Bangalore Call Girl Service👉📞 7304373326 👉📞 Just📲 Call Rajveer Call Girls Se...
👉Bangalore Call Girl Service👉📞 7304373326 👉📞 Just📲 Call Rajveer Call Girls Se...👉Bangalore Call Girl Service👉📞 7304373326 👉📞 Just📲 Call Rajveer Call Girls Se...
👉Bangalore Call Girl Service👉📞 7304373326 👉📞 Just📲 Call Rajveer Call Girls Se...Sheetaleventcompany
 
Budhwar Peth ( Call Girls ) Pune 6297143586 Hot Model With Sexy Bhabi Ready...
Budhwar Peth ( Call Girls ) Pune  6297143586  Hot Model With Sexy Bhabi Ready...Budhwar Peth ( Call Girls ) Pune  6297143586  Hot Model With Sexy Bhabi Ready...
Budhwar Peth ( Call Girls ) Pune 6297143586 Hot Model With Sexy Bhabi Ready...tanu pandey
 
surat Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
surat Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetsurat Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
surat Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetCall Girls Chandigarh
 
💞 Safe And Secure Call Girls Coimbatore 🧿 9332606886 🧿 High Class Call Girl S...
💞 Safe And Secure Call Girls Coimbatore 🧿 9332606886 🧿 High Class Call Girl S...💞 Safe And Secure Call Girls Coimbatore 🧿 9332606886 🧿 High Class Call Girl S...
💞 Safe And Secure Call Girls Coimbatore 🧿 9332606886 🧿 High Class Call Girl S...India Call Girls
 
Independent Call Girls Service Chandigarh Sector 17 | 8868886958 | Call Girl ...
Independent Call Girls Service Chandigarh Sector 17 | 8868886958 | Call Girl ...Independent Call Girls Service Chandigarh Sector 17 | 8868886958 | Call Girl ...
Independent Call Girls Service Chandigarh Sector 17 | 8868886958 | Call Girl ...Sheetaleventcompany
 
Call Girls Service Mohali {7435815124} ❤️VVIP PALAK Call Girl in Mohali Punjab
Call Girls Service Mohali {7435815124} ❤️VVIP PALAK Call Girl in Mohali PunjabCall Girls Service Mohali {7435815124} ❤️VVIP PALAK Call Girl in Mohali Punjab
Call Girls Service Mohali {7435815124} ❤️VVIP PALAK Call Girl in Mohali PunjabSheetaleventcompany
 
vadodara Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
vadodara Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetvadodara Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
vadodara Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetCall Girls Chandigarh
 
visakhapatnam Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
visakhapatnam Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetvisakhapatnam Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
visakhapatnam Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real MeetCall Girls Chandigarh
 
Call Girls Service Chandigarh Sexy Video ❤️🍑 8511114078 👄🫦 Independent Escort...
Call Girls Service Chandigarh Sexy Video ❤️🍑 8511114078 👄🫦 Independent Escort...Call Girls Service Chandigarh Sexy Video ❤️🍑 8511114078 👄🫦 Independent Escort...
Call Girls Service Chandigarh Sexy Video ❤️🍑 8511114078 👄🫦 Independent Escort...Sheetaleventcompany
 

Último (20)

Rishikesh Call Girls Service 6398383382 Real Russian Girls Looking Models
Rishikesh Call Girls Service 6398383382 Real Russian Girls Looking ModelsRishikesh Call Girls Service 6398383382 Real Russian Girls Looking Models
Rishikesh Call Girls Service 6398383382 Real Russian Girls Looking Models
 
9316020077📞Majorda Beach Call Girls Numbers, Call Girls Whatsapp Numbers Ma...
9316020077📞Majorda Beach Call Girls  Numbers, Call Girls  Whatsapp Numbers Ma...9316020077📞Majorda Beach Call Girls  Numbers, Call Girls  Whatsapp Numbers Ma...
9316020077📞Majorda Beach Call Girls Numbers, Call Girls Whatsapp Numbers Ma...
 
Escorts Lahore || 🔞 03274100048 || Escort service in Lahore
Escorts Lahore || 🔞 03274100048 || Escort service in LahoreEscorts Lahore || 🔞 03274100048 || Escort service in Lahore
Escorts Lahore || 🔞 03274100048 || Escort service in Lahore
 
Sexy Call Girl Dharmapuri Arshi 💚9058824046💚 Dharmapuri Escort Service
Sexy Call Girl Dharmapuri Arshi 💚9058824046💚 Dharmapuri Escort ServiceSexy Call Girl Dharmapuri Arshi 💚9058824046💚 Dharmapuri Escort Service
Sexy Call Girl Dharmapuri Arshi 💚9058824046💚 Dharmapuri Escort Service
 
Sexy Call Girl Nagercoil Arshi 💚9058824046💚 Nagercoil Escort Service
Sexy Call Girl Nagercoil Arshi 💚9058824046💚 Nagercoil Escort ServiceSexy Call Girl Nagercoil Arshi 💚9058824046💚 Nagercoil Escort Service
Sexy Call Girl Nagercoil Arshi 💚9058824046💚 Nagercoil Escort Service
 
AECS Layout Escorts (Bangalore) 9352852248 Women seeking Men Real Service
AECS Layout Escorts (Bangalore) 9352852248 Women seeking Men Real ServiceAECS Layout Escorts (Bangalore) 9352852248 Women seeking Men Real Service
AECS Layout Escorts (Bangalore) 9352852248 Women seeking Men Real Service
 
Call Girls in Udaipur Girija Udaipur Call Girl ✔ VQRWTO ❤️ 100% offer with...
Call Girls in Udaipur  Girija  Udaipur Call Girl  ✔ VQRWTO ❤️ 100% offer with...Call Girls in Udaipur  Girija  Udaipur Call Girl  ✔ VQRWTO ❤️ 100% offer with...
Call Girls in Udaipur Girija Udaipur Call Girl ✔ VQRWTO ❤️ 100% offer with...
 
❤️Ludhiana Call Girls ☎️98157-77685☎️ Call Girl service in Ludhiana☎️Ludhiana...
❤️Ludhiana Call Girls ☎️98157-77685☎️ Call Girl service in Ludhiana☎️Ludhiana...❤️Ludhiana Call Girls ☎️98157-77685☎️ Call Girl service in Ludhiana☎️Ludhiana...
❤️Ludhiana Call Girls ☎️98157-77685☎️ Call Girl service in Ludhiana☎️Ludhiana...
 
(Deeksha) 💓 9920725232 💓High Profile Call Girls Navi Mumbai You Can Get The S...
(Deeksha) 💓 9920725232 💓High Profile Call Girls Navi Mumbai You Can Get The S...(Deeksha) 💓 9920725232 💓High Profile Call Girls Navi Mumbai You Can Get The S...
(Deeksha) 💓 9920725232 💓High Profile Call Girls Navi Mumbai You Can Get The S...
 
(Big Boobs Indian Girls) 💓 9257276172 💓High Profile Call Girls Jaipur You Can...
(Big Boobs Indian Girls) 💓 9257276172 💓High Profile Call Girls Jaipur You Can...(Big Boobs Indian Girls) 💓 9257276172 💓High Profile Call Girls Jaipur You Can...
(Big Boobs Indian Girls) 💓 9257276172 💓High Profile Call Girls Jaipur You Can...
 
👉Bangalore Call Girl Service👉📞 7304373326 👉📞 Just📲 Call Rajveer Call Girls Se...
👉Bangalore Call Girl Service👉📞 7304373326 👉📞 Just📲 Call Rajveer Call Girls Se...👉Bangalore Call Girl Service👉📞 7304373326 👉📞 Just📲 Call Rajveer Call Girls Se...
👉Bangalore Call Girl Service👉📞 7304373326 👉📞 Just📲 Call Rajveer Call Girls Se...
 
Budhwar Peth ( Call Girls ) Pune 6297143586 Hot Model With Sexy Bhabi Ready...
Budhwar Peth ( Call Girls ) Pune  6297143586  Hot Model With Sexy Bhabi Ready...Budhwar Peth ( Call Girls ) Pune  6297143586  Hot Model With Sexy Bhabi Ready...
Budhwar Peth ( Call Girls ) Pune 6297143586 Hot Model With Sexy Bhabi Ready...
 
surat Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
surat Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetsurat Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
surat Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
💞 Safe And Secure Call Girls Coimbatore 🧿 9332606886 🧿 High Class Call Girl S...
💞 Safe And Secure Call Girls Coimbatore 🧿 9332606886 🧿 High Class Call Girl S...💞 Safe And Secure Call Girls Coimbatore 🧿 9332606886 🧿 High Class Call Girl S...
💞 Safe And Secure Call Girls Coimbatore 🧿 9332606886 🧿 High Class Call Girl S...
 
Independent Call Girls Service Chandigarh Sector 17 | 8868886958 | Call Girl ...
Independent Call Girls Service Chandigarh Sector 17 | 8868886958 | Call Girl ...Independent Call Girls Service Chandigarh Sector 17 | 8868886958 | Call Girl ...
Independent Call Girls Service Chandigarh Sector 17 | 8868886958 | Call Girl ...
 
Call Girls Service Mohali {7435815124} ❤️VVIP PALAK Call Girl in Mohali Punjab
Call Girls Service Mohali {7435815124} ❤️VVIP PALAK Call Girl in Mohali PunjabCall Girls Service Mohali {7435815124} ❤️VVIP PALAK Call Girl in Mohali Punjab
Call Girls Service Mohali {7435815124} ❤️VVIP PALAK Call Girl in Mohali Punjab
 
vadodara Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
vadodara Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetvadodara Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
vadodara Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
visakhapatnam Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
visakhapatnam Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meetvisakhapatnam Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
visakhapatnam Call Girls 👙 6297143586 👙 Genuine WhatsApp Number for Real Meet
 
Punjab Call Girls Contact Number +919053,900,678 Punjab Call Girls
Punjab Call Girls Contact Number +919053,900,678 Punjab Call GirlsPunjab Call Girls Contact Number +919053,900,678 Punjab Call Girls
Punjab Call Girls Contact Number +919053,900,678 Punjab Call Girls
 
Call Girls Service Chandigarh Sexy Video ❤️🍑 8511114078 👄🫦 Independent Escort...
Call Girls Service Chandigarh Sexy Video ❤️🍑 8511114078 👄🫦 Independent Escort...Call Girls Service Chandigarh Sexy Video ❤️🍑 8511114078 👄🫦 Independent Escort...
Call Girls Service Chandigarh Sexy Video ❤️🍑 8511114078 👄🫦 Independent Escort...
 

ASCO Review 2016 Colorectal Cancer

  • 1. The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Updates in Colorectal Cancer 2016 Kristen K. Ciombor, MD, MSCI Assistant Professor Division of Medical Oncology
  • 2. Outline § Primary tumor sidedness in colorectal cancer §  CALGB/SWOG 80405 § Immunotherapy in colorectal and anal cancer §  Immunoscore in early stage colon cancer §  Pembrolizumab in MSI-H mCRC §  Nivolumab +/- ipilimumab in mCRC §  Cobimetinib + atezolizumab in MSS mCRC §  Nivolumab in metastatic anal cancer 2
  • 4. Impact of primary tumor location on Overall Survival and Progression Free Survival in patients with metastatic colorectal cancer: Analysis of CALGB/SWOG 80405 (Alliance) A Venook, D Niedzwiecki, F Innocenti, B Fruth, C Greene, BH O’Neil, J Shaw, J Atkins, LE Horvath, B Polite, JA Meyerhardt, EM O’Reilly, R Goldberg, HS Hochster, CD Blanke, R Schilsky, RJ Mayer, M Bertagnolli, HJ Lenz for SWOG and the ALLIANCE
  • 5. CALGB/SWOG 80405 Chemo + Cetuximab Chemo + Bevacizumab 1ST LINE MET / ADVANCED COLORECTAL KRAS wt FOLFIRI or FOLFOX MD choice ASCO, JUNE, 2014 Chemo + Cetuximab OS = 32.0 mos PFS = 11.4 mos Chemo + Bevacizumab OS = 31.2 mos PFS = 11.3 mosN = 1137 CONCLUSION: NO DIFFERENCE OS better than anticipated in both arms: Treatment effect and/or Patient selection All RAS wt ESMO, SEP, 2014 N = 526
  • 6. CALGB 80405: Side of primary tumor Methods •  Population –  KRAS wt pts in main analysis –  Pre-amendment KRAS mut pts •  Data extraction –  Study chart, other supporting information if available •  Side of 1° determination –  Definitive information: •  Colonoscopy, surgical or imaging report Presented by:
  • 7. Presented by: 80405: Side of Primary Tumors LEFT N = 732 (68%) RIGHT N = 293 (27%) TRANSVERSE N = 66 COULD NOT DETERMINE N = 46
  • 8. Bettington, et al. Histopathology. 2013. Embryology: The origin of the colon RIGHT COLON LEFT COLON
  • 9. 80405: Overall Survival by Sidedness Presented by: Side N (Events) Median (95% CI) HR (95% CI) p Left 732 (550) 33.3 (31.4-35.7) 1.55 (1.32-1.82)  < 0.0001 Right 293 (242) 19.4 (16.7-23.6) Right Left
  • 10. 80405: OS by Sidedness (Bevacizumab) Presented by: Side N (Events) Median (95% CI) HR(95% CI) p Left 356 (280) 31.4 (28.3-33.6) 1.32 (1.05-1.65)   0.01   Right 150 (121) 24.2 (17.9-30.3) LeftRight
  • 11. 80405: OS by Sidedness (Cetuximab) Presented by: Side N (Events) Median (95% CI) HR (95% CI) p Left 376 (270) 36.0 (32.6-40.3) 1.87 (1.48-2.32)   <0.0001   Right 143 (121) 16.7 (13.1-19.4) Left Right
  • 12. 80405: Sidedness is Prognostic Overall Survival (OS) Presented by: KRAS wt N = 1025 Right 1° Median OS (mos) Left 1° Median OS (mos) Hazard Ratio 95% CI (adjusted*) P (adjusted*) All pts 19.4 33.3 1.55 (1.32,1.82) P < 0.0001 Cet 16.7 36.0 1.87 (1.48, 2.32) P < 0.0001 Bev 24.2 31.4 1.32 (1.05, 1.65) P = 0.01 *Adjusted for biologic, protocol chemotherapy, prior adjuvant therapy, prior RT, age, sex, synchronous disease, in place primary, liver metastases 19.3 MONTHS IS A BIG DIFFERENCE !!
  • 13. 80405: Overall Survival by Sidedness and Biologic Presented by: 31.4 (28.3-33.6) 36.0 (32.6-40.3) 24.2 (17.9-30.3) 16.7 (13.1-19.4)
  • 14. Summary of Primary Tumor Sidedness in mCRC § Patients with R-sided primaries had much worse outcomes than pts with L-sided primaries, independent of biologic arm (prognostic) § 1st line cetuximab and bevacizumab have different treatment effects in sidedness subgroups § Sidedness is likely a surrogate for tumor biology § Future trials to stratify patients by primary sidedness § Remember: this is a retrospective ad hoc analysis; these results will factor in when making tx decisions but this is not the whole story 14
  • 16. Slide 1 Presented By Jerome Galon at 2016 ASCO Annual Meeting
  • 17. Slide 6 Presented By Jerome Galon at 2016 ASCO Annual Meeting
  • 18. Slide 11 Presented By Jerome Galon at 2016 ASCO Annual Meeting
  • 19. Slide 14 Presented By Jerome Galon at 2016 ASCO Annual Meeting
  • 20. Slide 18 Presented By Jerome Galon at 2016 ASCO Annual Meeting
  • 21. Slide 22 Presented By Jerome Galon at 2016 ASCO Annual Meeting
  • 22. Summary of Immunoscore in Early Stage Colon CA § Time to recurrence was significantly longer in patients with stage I/II/III colon cancer and high immunoscore § Immunoscore is significant in multivariate analyses in all cohorts (TS, IVS, EVS) § Potential identification of a high-risk stage II group § Immunoscore predicts TTR, DFS and OS § How much is microsatellite instability contributing? § Future immune-based assay for cancer: TNM-Immune? 22
  • 24. Slide 1 Presented By Dung Le at 2016 ASCO Annual Meeting
  • 25. Slide 2 Presented By Dung Le at 2016 ASCO Annual Meeting
  • 26. Slide 5 Presented By Dung Le at 2016 ASCO Annual Meeting
  • 27. Slide 8 Presented By Dung Le at 2016 ASCO Annual Meeting
  • 28. Slide 11 Presented By Dung Le at 2016 ASCO Annual Meeting
  • 29. Slide 15 Presented By Dung Le at 2016 ASCO Annual Meeting
  • 30. Slide 18 Presented By Dung Le at 2016 ASCO Annual Meeting
  • 31. Slide 19 Presented By Dung Le at 2016 ASCO Annual Meeting
  • 32. Summary of Pembrolizumab in MSI-H mCRC § PD-1 blockade with pembrolizumab is highly active in dMMR mCRC § Complete and durable responses are seen in >50% of patients § 18% have reached the two year mark on tx and patients are under surveillance § Next/current trials: single agent pembrolizumab in 1st line MSI-H mCRC, adjuvant trial, pembro + FOLFOX 32
  • 34. Nivolumab ± Ipilimumab in Treatment of Patients With Metastatic Colorectal Cancer With and Without High Microsatellite Instability: <br />CheckMate 142 Interim Results Presented By Michael Overman at 2016 ASCO Annual Meeting
  • 35. Ipilimumab and Nivolumab <br />Mechanisms of Action Presented By Michael Overman at 2016 ASCO Annual Meeting
  • 36. Phase 2 CheckMate 142 Study Design: Microsatellite Stable (MSS) Cohort Presented By Michael Overman at 2016 ASCO Annual Meeting
  • 37. Phase 2 CheckMate 142 Study Design: <br />MSI-H Cohort Presented By Michael Overman at 2016 ASCO Annual Meeting
  • 38. Investigator-Assessed Best Overall Response in <br />Patients With MSI-H Receiving Nivolumab Monotherapy Presented By Michael Overman at 2016 ASCO Annual Meeting
  • 39. Investigator-Assessed Best Overall Response in <br />Patients With MSI-H Receiving Nivolumab + Ipilimumab Presented By Michael Overman at 2016 ASCO Annual Meeting
  • 40. Best Reduction in Target Lesion Size <br />in Patients With MSI-H Presented By Michael Overman at 2016 ASCO Annual Meeting
  • 41. OS in Patients With MSI-H<br />Nivolumab ± Ipilimumab in Metastatic CRC Presented By Michael Overman at 2016 ASCO Annual Meeting
  • 42. Treatment-Related Adverse Events <br />in ≥ 15% of Patients With MSI-H Presented By Michael Overman at 2016 ASCO Annual Meeting
  • 43. <br />Summary of Efficacy in Patients With MSS<br />Nivolumab ± Ipilimumab in Metastatic CRC Presented By Michael Overman at 2016 ASCO Annual Meeting
  • 44. Summary of Nivo +/- Ipi in mCRC § Nivolumab monotherapy and nivo + ipi showed encouraging activity in MSI-H mCRC (interim analysis) § Responses were durable in MSI-H patients § Tolerable safety profiles but increasing toxicities with combination therapy, consistent w/ observations in other solid tumors § Need final analysis prior to next trials 44
  • 46. Clinical activity and safety of cobimetinib and atezolizumab in colorectal cancer Presented By Johanna Bendell at 2016 ASCO Annual Meeting
  • 47. Slide 3 Presented By Johanna Bendell at 2016 ASCO Annual Meeting
  • 48. Atezolizumab: An Anti-PDL1 Antibody Presented By Johanna Bendell at 2016 ASCO Annual Meeting
  • 49. PD-L1 and MEK Inhibition: A Rational Combination Presented By Johanna Bendell at 2016 ASCO Annual Meeting
  • 50. Phase Ib Dose Escalation and Cohort Expansion Study (NCT01988896) Presented By Johanna Bendell at 2016 ASCO Annual Meeting
  • 51. Safety Summary Presented By Johanna Bendell at 2016 ASCO Annual Meeting
  • 52. Safety: Treatment-related AEs Presented By Johanna Bendell at 2016 ASCO Annual Meeting
  • 53. Efficacy: Confirmed Objective Response Presented By Johanna Bendell at 2016 ASCO Annual Meeting
  • 54. Efficacy: Change in Tumor Burden Presented By Johanna Bendell at 2016 ASCO Annual Meeting
  • 55. Efficacy: Duration of Treatment and Response Presented By Johanna Bendell at 2016 ASCO Annual Meeting
  • 56. Summary of Cobi + Atezo in MSS mCRC § Cobimetinib + atezolizumab was fairly tolerated in pts with refractory MSS mCRC § Combination therapy resulted in higher clinical response rate (17%) and 6-month OS (72%) than expected with either agent alone § Cobi may sensitize tumors to atezo by increasing MHC I expression on tumor cells, promoting intratumoral CD8 T cell accumulation § Next/current trial: Phase Ib expansion and phase III trial both ongoing 56
  • 58. NCI9673: A Multi-Institutional ETCTN Phase II Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal (SCCA) V. Morris1, K. Ciombor2, M.E. Salem3, H. Nimeiri4, S. Iqbal5, P. Singh6, B. Polite7, D. Deming8, E. Chan9, J.L. Wade10, T.S. Bekaii-Saab2, H.E. Uronis11, M.G. Pasia1, G. Bland1, R.A. Wolff1, A. Ohinata1, C. Ohaji1, J.E. Rogers1, P. Sharma1, C. Eng1 1The University of Texas MD Anderson Cancer Center, Houston, TX; 2The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital, Columbus, OH; 3Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; 4Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; 5University of Southern California/ Norris Comprehensive Cancer Center, Los Angeles, CA; 6Washington University, Siteman Cancer Center, St. Louis, MO; 7The University of Chicago, Chicago, IL; 8University of Wisconsin Hospitals and Clinics, Madison, WI; 9Vanderbilt University Medical Center, Nashville, TN; 10Cancer Care Center of Decatur, Decatur, IL; 11Duke University Medical Center, Durham, NC
  • 59. •  Approximately 80-95% of cases are linked to infection with human papillomavirus (HPV). •  The role of HPV in the tumorigenesis of SCCA provides rationale for the use of immune checkpoint blockade agents as a novel therapy for treatment of patients with a virally driven disease. Presented by: Cathy Eng, MD Rationale for Nivolumab in Metastatic SCCA: Morris VK et al. The Oncologist, 2015, Sarup-Hansen E et al. J Clin Oncol ,2014
  • 60. NCI#9673: Phase II Design of Nivolumab in Metastatic SCCA Presented by: Cathy Eng, MD Patients with metastatic squamous cell carcinoma of the anal canal - Treated with at least one prior therapy for metastatic disease - No prior immune therapies received as part of cancer treatment 12 patients treated initially with nivolumab 3mg/kg IV every 2 weeks Patients will be followed for best response using RECIST criteria 1.1 0 responses ≥1 response Stop trial Expand trial to include 25 additional patients with metastatic SCCA * HIV+ patients allowed •  Rapid enrollment in < 6 months •  Closed to enrollment as of 11/01/15 •  Simon Optimal, two- stage phase II study, Ho: p ≤ 0.05 and an alternative hypothesis Ha: p ≥ 0.20, •  α = 0.10 and a β = 0.10
  • 61. Primary Endpoint: Response Rate Presented by: Cathy Eng, MD Response Rate N (%) CR 2 (5.4%) PR 7 (18.9%) SD 17 (45.9%) PD 8 (21.6%) Unevaluable 3 (8.1%) ORR (ITT, N=37) 9 (24.3%) ORR (Evaluable, N=34) 9 (26.5%) Data cutoff date: 5/15/16
  • 62. -1 0 0 -9 0 -8 0 -7 0 -6 0 -5 0 -4 0 -3 0 -2 0 -1 0 0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0 P a tie n t %targetlesionreduction frombaselinebyRECIST1.1 P ro g re s s iv e D is e a s e S ta b le D is e a s e P a rtia l R e s p o n s e P R P D NCI#9673: Response Rate N=37 (ITT) N=34 (evaluable for RR) 2 CR’s 7 PR’s Presented by: Cathy Eng, MD Patients CR
  • 63. NCI#9673 Toxicities of Therapy Toxicity (N=37) Grade (%) 1 2 3 4 Fatigue 17 (46) 7 (19) 1 (3) - Anemia 13 (35) 11 (30) 2 (5) - Rash 8 (22) 2 (5) 1 (3) - Constipation 8 (22) 2 (5) - - Diarrhea 8 (22) - - - Anorexia 5 (14) 4 (11) - - Weight loss 5 (14) 1 (3) - - Arthralgia 3 (8) 3 (8) - - Hyperglycemia 3 (8) 1 (3) - - Lymphedema 1 (3) 1 (3) - - Pneumonitis - 1 (3) - - Nausea 2 (5) - - - Hypothyroidism 1 (3) 1 (3) 1 (3) - Presented by: Cathy Eng, MD
  • 64. Summary of Nivolumab in Anal Cancer § First prospective phase II trial completed in refractory mSCC of anal canal; <6 month accrual § Encouraging response rates in a “rare” cancer with few treatment options for metastatic disease § Nivolumab was well tolerated, even in HIV+ patients § Future trial: amendment of NCI 9673—pilot of nivolumab + ipilimumab 64
  • 65. Thank You To learn more about Ohio State’s cancer program, please visit cancer.osu.edu or follow us in social media: 65